本帖最后由 成长的烦恼 于 2012-6-27 20:19 编辑
* S, m9 i2 t$ n( O; ?; k4 ]( r" F- ]5 s- _7 L6 ?% `; J' G
clinicaltrials上的三期临床链接
3 U1 X7 r& Q$ ~
) e6 m1 T" D7 i! C# @ z5 B3 \http://clinicaltrials.gov/ct2/sh ... mp;show_locs=Y#locn4 y+ G( D( s" @) I. U6 E: y
1 W1 }) Y: Q8 T; h' `
中国参加临床实验的城市
; p9 e( U2 A2 q( }" q1 l0 q% q" i( k+ A
China, Guangdong / E; `, k7 k: o) Y
0 Y0 D, P f$ e* r0 [
Guangzhou, Guangdong, China, 510515 : b- L3 A$ x% ~- V! ]9 G" A/ @
& C7 Z+ B, T* ] G
Guangzhou, Guangdong, China, 510060 ! t/ ]. {3 S* h- e
China, Jiangsu ; i! c$ R4 X, ?
6 q G; J X Q- T0 x
Nanjing, Jiangsu, China, 210009 ! l+ B* s- k9 ?6 t
% o3 q8 K3 j% M9 Y* Z0 y
Nanjing, Jiangsu, China, 210002
6 x$ `% c* X, w" ^. }: bChina, Shandong
# z! t3 @8 [; J: h9 g 2 `4 b7 A0 {, l$ \& p# y7 x
Qingdao, Shandong, China, 266003
. h; `0 J; B9 B% t7 g' |- q: cChina
8 U0 O3 `5 J9 b/ A7 \8 C , n% }: K9 Q5 o! m; j/ B
Beijing, China, 100021 6 r+ _5 B' N8 P5 [1 s; F8 P8 ?; N
) A9 O4 j4 d+ ]$ w, s# m6 l1 L$ o& aBeijing, China, 100071 4 `5 h6 L) q7 [7 X: E6 C
* h2 i9 a3 e9 v6 tChangchun, China, 130021 7 `. q$ F" r# H) w5 u
& h; E6 P* j7 t2 X B% E' B3 e# `
Chongqing, China, 400042
+ ?3 ?8 x9 G- I! V- u
! p. ~+ \1 I4 D2 c0 CChongqing, China, 400038 % z8 r# c/ X# I5 b. e
* Z& S1 t5 Y6 j1 jFuzhou, China, 350014
- q7 X' c, I! c3 I$ R 9 Z1 r% M5 ?0 q" ~
Fuzhou, China, 350025
& L) z/ i; T' ~. N; m( a- u% ?: i+ p
5 W6 Q% k8 x, ~! M- IHa'erbin, China, 150040 5 G$ y- {0 M$ Q. C* a1 A
3 f L: d; @) J0 B6 b" H9 Q& d
Hanghzou, China, 310009
9 l7 w# W6 d% z
2 U* Z# f1 i% Y/ p( _/ |, ^Shanghai, China, 200001
, s8 b, u# f" f# B/ }+ \ 4 T$ U2 j: v$ Z! ~; O9 x: Q
Shanghai, China, 200030 1 F- E+ K8 v& f: m% R$ `; E
F. w9 e- I5 c0 q0 R+ \
Tianjin, China : ] S, @+ d5 M+ A4 I4 m% B# u+ n
' [2 S, K0 r! g; y* \3 r
该实验已停止招募,重新开的临床请见临床专用贴。 |